RVMD Revolution Medicines
- 39.190
- +0.370+0.95%
Revolution Medicines News
Analysts Are Bullish on Top Healthcare Stocks: Intuitive Surgical (ISRG), Revolution Medicines (RVMD)
Oppenheimer Sticks to Their Buy Rating for Revolution Medicines (RVMD)
Revolution Medicines Receives Buy Rating Amid Promising Cancer Treatment Data and Expanded Market Opportunities
Needham: Maintaining the Revolution Medicines (RVMD.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $36.00 to $46.00.
Revolution Medicines Analyst Ratings
Raymond James: Raised Revolution Medicines (RVMD.US) rating from superior market to strong buying rating, and adjusted target price from $36.00 to $48.00.
Revolution Medicines Analyst Ratings
Needham: Maintaining the Revolution Medicines (RVMD.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $36.00 to $36.00.
Revolution Medicines Analyst Ratings
Revolution Medicines' Robust Cancer Drug Pipeline Justifies Buy Rating
Revolution Medicines Analyst Ratings
Buy Rating on Revolution Medicines Amid Promising RMC-6236 Trials for Multiple Cancer Treatments
HC Wainwright & Co. Maintains Buy on Revolution Medicines, Raises Price Target to $44
Revolution Medicines Analyst Ratings
Revolution Medicines (RVMD) Receives a Buy From TD Cowen
Buy Rating Affirmed for Revolution Medicines: Advancing RAS Inhibitors and Strong Financial Outlook
Revolution Medicines Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Celldex (CLDX), Revolution Medicines (RVMD)
Wedbush Adjusts Revolution Medicines' Price Target to $42 From $41, Keeps Outperform Rating
TD Cowen Sticks to Their Buy Rating for Revolution Medicines (RVMD)
Analysis
Price Target
No Data
